Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CXCL5 neutralizing monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- National Yang Ming Chiao Tung University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intperitoneal, Intravenous
01
Overview
An anti-CXCL5 neutralizing monoclonal antibody is a therapeutic agent designed to target and neutralize C-X-C motif chemokine ligand 5 (CXCL5), a pro-inflammatory chemokine that acts through the CXCR2 receptor. CXCL5 is involved in neutrophil chemotaxis, inflammation, and tissue remodeling, and its upregulation is associated with diabetic kidney disease (DKD), vascular complications of diabetes, and various cancers. In preclinical models of diabetic kidney disease, treatment with an anti-CXCL5 neutralizing antibody has been shown to improve renal function, reduce urinary albumin-to-creatinine ratios, and attenuate glomerular hypertrophy, glomerulosclerosis, and renal fibrosis.
- Other names
- anti-CXCL5 antibodyanti-CXCL-5 antibodyanti-CXCL 5 antibodyanti-CXCL5 monoclonal antibodyanti-CXCL-5 monoclonal antibodyanti-CXCL 5 monoclonal antibodyCXCL5 neutralizing antibodyCXCL-5 neutralizing antibodyCXCL 5 neutralizing antibody
02
Targets
CXCL5 (C-X-C motif chemokine ligand 5)
Beyond the preview
Go deeper on anti-CXCL5 neutralizing monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CXCL5 neutralizing monoclonal antibody.